About the Company
NeurAxis, Inc
BUSINESS DESCRIPTION
NeurAxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. NeurAxis is dedicated to advancing the science with its’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. We believe that superior science, evidence-based research, and building on its unparalleled body of clinical evidence is necessary for adoption by the medical...
NeurAxis, Inc News
-
The Zacks Analyst Blog Highlights Microsoft, NVIDIA, Bank of America, BK Technol...
06/27/2025 08:53 AMMSFT, NVDA, and BAC lead Zacks' top stock picks, while microcaps BKTI and NRXS show surprising strength in niche markets....
-
Top Stock Reports for Microsoft, NVIDIA & Bank of America...
06/26/2025 08:34 PMMSFT, NVDA and BAC shine in Zacks' top picks, with AI, cloud, and higher rates driving strong growth projections....
-
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding ...
06/17/2025 12:00 PMCARMEL, Ind., June 17, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commer...
-
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Re...
06/10/2025 12:00 PMPractice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical Nerve Field Stimulation (PENFS) as a ...
-
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference o...
05/27/2025 12:00 PMCARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commerc...
-
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering...
05/22/2025 05:03 PMStrengthens Balance Sheet and Provides Growth CapitalCARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE ...
-
NeurAxis Announces $5.0 Million Registered Direct Offering...
05/21/2025 11:00 AMCARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commerc...
-
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Fun...
05/20/2025 12:00 PM• Significantly expands IB-Stim’s total addressable market • Clearance covers patients aged 8–21 • Seamless go-to-market strategy with existing reimbu...
-
NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones...
05/15/2025 04:06 PMNRXS posts strong first-quarter 2025 earnings with robust revenue growth and FDA milestones, driving stock gains as investors eye broader insurance coverage and...
Disclaimer: